ArticleJournal of gastrointestinal oncology2026
A single-cell and machine learning framework identifies CAFs-associated signatures linking stromal heterogeneity to immune regulation in pancreatic cancer.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC), contributing to tumor progression, metabolic reprogramming, and immune suppression. However, the functional heterogeneity of CAFs and their prognostic and immunological significance remain incompletely understood. This study aimed to characterize CAFs heterogeneity in PDAC and develop a robust CAFs-associated signature (CAFAS) for prognostic prediction and immune stratification. Methods: Single-cell RNA sequencing (scRNA-seq) datasets from PDAC were analyzed to identify and characterize CAFs subpopulations. Distinct CAFs clusters were annotated, and prognostic CAFs-associated genes were screened to construct a CAFAS through benchmarking seven machine learning algorithms under a nested cross-validation framework. The predictive performance of CAFAS was validated across five independent cohorts. Comprehensive analyses, including immune infiltration assessment, pathway enrichment, and drug sensitivity prediction, were performed to elucidate the biological and clinical implications of CAFAS. Results: Five CAFs subtypes with distinct molecular and functional features were identified, among which ADM+ALDOA+ CAFs were associated with poor prognosis and enriched in glycolytic and proliferative pathways. The resulting CAFAS demonstrated strong and consistent prognostic performance across multiple cohorts, accurately stratifying patients by overall survival and therapeutic responsiveness. High CAFAS scores correlated with cell cycle activation and glycolytic pathways, whereas low CAFAS scores were associated with immune activation and lipid metabolism. CAFAS also effectively predicted immune infiltration, immunotherapy response, and drug sensitivity. Conclusions: This study establishes a robust CAFs-associated prognostic model that integrates single-cell transcriptomic insights with machine learning to capture CAFs heterogeneity in PDAC. CAFAS provides a valuable framework for precision prognosis, immunotherapy stratification, and the identification of potential therapeutic targets aimed at remodeling the immunosuppressive stroma in PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.